Hormone Receptor Expression and Activity for Different Tumour
Locations in Patients with Advanced and Recurrent Endometrial
Carcinoma

J 2024

Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN et. al.

Basic information

Original name

Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

Authors

Edition

Cancers, BASEL, MDPI, 2024, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers16112084

UT WoS

001246772500001

Keywords in English

endometrial cancer; hormone receptor; tumour location

Abstract

V originále

Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.

Citovat

LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER, Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO and Johanna M A PIJNENBORG. Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. Cancers. BASEL: MDPI, 2024, vol. 16, No 11, p. 1-19. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers16112084.

@article{2416241,
   author = {Luijten, Maartje M W and Jan, van Weelden Willem and Lalisang, Roy I and Bulten, Johan and Lindemann, Kristina and van Beekhuizen, Heleen J and Trum, Hans and Boll, Dorry and Werner, Henrica M J and van Lonkhuijzen, Luc R C W and Yigit, Refika and Krakstad, Camilla and Witteveen, Petronella O and Galaal, Khadra and van Ginkel, Alexandra A and Bignotti, Eliana and Weinberger, Vít and Sweegers, Sanne and Eriksson, Ane Gerda Z and Keizer, Diederick M and Anja, van de Stolpe and Romano, Andrea and Pijnenborg, Johanna M A},
   article_location = {BASEL},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/cancers16112084},
   keywords = {endometrial cancer; hormone receptor; tumour location},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma},
   url = {https://www.mdpi.com/2072-6694/16/11/2084},
   volume = {16},
   year = {2024}
}

TY  - JOUR
ID  - 2416241
AU  - Luijten, Maartje M W - Jan, van Weelden Willem - Lalisang, Roy I - Bulten, Johan - Lindemann, Kristina - van Beekhuizen, Heleen J - Trum, Hans - Boll, Dorry - Werner, Henrica M J - van Lonkhuijzen, Luc R C W - Yigit, Refika - Krakstad, Camilla - Witteveen, Petronella O - Galaal, Khadra - van Ginkel, Alexandra A - Bignotti, Eliana - Weinberger, Vít - Sweegers, Sanne - Eriksson, Ane Gerda Z - Keizer, Diederick M - Anja, van de Stolpe - Romano, Andrea - Pijnenborg, Johanna M A
PY  - 2024
TI  - Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
JF  - Cancers
VL  - 16
IS  - 11
SP  - 1-19
EP  - 1-19
PB  - MDPI
SN  - 20726694
KW  - endometrial cancer
KW  - hormone receptor
KW  - tumour location
UR  - https://www.mdpi.com/2072-6694/16/11/2084
N2  - Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
ER  -

LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER, Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO and Johanna M A PIJNENBORG. Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. \textit{Cancers}. BASEL: MDPI, 2024, vol.~16, No~11, p.~1-19. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers16112084.

Detailed Information on Publication Record